Z-0349-2023 Class III Terminated
FDA device recall Z-0349-2023 was initiated by Primus Corporation Dba Trinity Biotech on Oct 5, 2021 and is designated Class III. Reason for recall: The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. The unacceptable Control Level 1 value results in the… The recall status is terminated (terminated Aug 9, 2023). Affected quantity: 340 kits.
Recall details
- Product Type
- Devices
- Report Date
- Dec 7, 2022
- Initiation Date
- Oct 5, 2021
- Termination Date
- Aug 9, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 340 kits
Product description
A. MENARINI diagnostics Hb 9210 PREMIER, LEVEL1, LEVEL II, Hemoglobin A1c Controls for hemoglobin A1c Assay, REF 45052, part number 05-01-0926, A1c analysis
Reason for recall
The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. The unacceptable Control Level 1 value results in the Analyzer generating an error code which stops further testing and nullifies associated patient samples, resulting in a delay in patient results and a potential delay in therapeutic modifications.
Distribution pattern
Turkey, India, Romania, Thailand, Vietnam, S. Korea, Peru, Pakistan Austria, UAE, Chile, Italy.
Code information
Lot 12161
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-0349-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026